Mechanism of increased mortality risk with erythropoietin treatment to higher hemoglobin targets.

@article{Fishbane2007MechanismOI,
  title={Mechanism of increased mortality risk with erythropoietin treatment to higher hemoglobin targets.},
  author={Steven A Fishbane and Anatole Besarab},
  journal={Clinical journal of the American Society of Nephrology : CJASN},
  year={2007},
  volume={2 6},
  pages={1274-82}
}
Recent randomized, controlled trials indicate that there is a strong trend for increased risk for death or adverse composite outcomes with erythropoiesis-stimulating agent treatment in kidney disease to hemoglobin targets higher than those currently recommended. The failure of these trials to find a benefit of higher hemoglobin is in stark contrast to findings from large, observational, population-based studies that continue to demonstrate the association of low hemoglobin with adverse outcomes… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 1 time. VIEW TWEETS

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 47 extracted citations

Zum optimalen Hämoglobinzielbereich bei renaler Anämie

Medizinische Klinik • 2008
View 7 Excerpts
Highly Influenced

Anemia in chronic kidney disease: new advances.

Heart failure clinics • 2010
View 9 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…